EUCTR2010-023168-41-SK进行中（未招募）1 期
A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 45.5, 90.9 and 181.8 µg b.i.d. administered via Respimat® inhaler and fluticasone propionate HFA MDI 220 µg b.i.d. in patients with asthma inadequately controlled on low dose ICS therapy.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 755
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To enter run-in period following completion of pre-screening period:
- •1.All patients [and parents or legal guardian of the adolescent age group (12-17 years)] must sign and date an ICF at Visit 0 consistent with ICH-GCP guidelines and local legislation prior to participation in trial, which includes medication washout and restrictions.
- •2.Male and female patients aged at least 12 to 65 years.
- •3.All patients must have a history of asthma diagnosed by a physician for at least three months at the time of enrolment into the trial according to the 2009 Global Initiative for Asthma (GINA) Guidelines [P10-03196]. The initial diagnosis of asthma must have been made before the age of 40 years.
- •4.All patients must be on a maintenance treatment with either medium-dose ICS plus LABA or high-dose ICS without LABA, stable for at least six weeks prior to Visit 1 (see also Section 3.3.1 and Appendix 10.3).
- •5.All patients must have a pre-bronchodilator FEV1 of > 60-90% of predicted normal and an ACQ-6 mean score of < 1.5 at the pre-screening Visits 1 and 2.
- •Age group 12 - 17 years:
- •Predicted normal values will be calculated according to equations from Wang et al [R02-0874] (refer to Appendix 10.3).
- •Age group 18 - 65 years:
- •Predicted normal values will be calculated according to ECSC [R94-1408] (refer to Appendix 10.3).
- •The spirometer used to assess lung function (MasterScope® CT) will be programmed with the equations for the two age groups.
- •6.Patients must be never-smokers or ex-smokers with a smoking history of <10 pack-years and smoking cessation at least one year prior to screening (see Appendix 10.3 for calculation).
- •7.Patients must be able to use Respimat® inhaler and MDI correctly (refer to Appendix 10.1)
- •8.Patients must be able to perform all trial-related procedures including technically acceptable pulmonary function tests and electronic PEF measurements, and must be able to maintain records during the study period as required in the protocol (AM2+ including eDiary - eDiary compliance of at least 80 % is required, refer to Section 6.2 and Appendix 10.6 for instructions).
- •To enter treatment period following additional criteria have to be met:
- •9.All patients must have an improvement in FEV1 > 12 % and an absolute change of at least 200 mL within 15-30 min after administration of 400 µg salbutamol/albuterol HFA MDI as demonstrated at Visit 1 or during one of the visits during the run-in period.
- •10.During the run-in period (at the same clinic visit) all patients must be both symptomatic (ACQ-6 mean score = 1.5) and have shown a decrease in morning pre-bronchodilator FEV1 = 10% and = 25% from pre-screening baseline FEV1 at Visit 2.
- •In the event a patient demonstrates a drop in morning FEV1 > 25%, it is the investigator’s clinical judgement whether it is clinically safe to randomise the patient or to withdraw the patient from the study and to re-start pre-trial controller medication and/or an oral steroid treatment.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with significant pulmonary disease* other than asthma or other significant medical conditions (as determined by medical history, examination and clinical investigations at screening)** that may, in the opinion of the investigator, result in any of the following: (i) put the patient at risk because of participation in this trial or (ii) influence the results of the trial or (iii) cause concern regarding the patient’s ability to participate in the trial.
- •* e.g. COPD, tuberculosis (TB) during the past two years or uncured TB, pulmonary fibrosis, cystic fibrosis and others.
- •** e.g. cardiac, gastro-intestinal, hepatic, renal, metabolic, dermatologic, neurological, haematological, oncological and psychiatric.
- •2.Patients with a clinically relevant, abnormal screening haematology and/or blood chemistry finding, if the abnormality indicates a significant disease as defined in exclusion criterion no. 1.
- •3.Patients with a history of upper or lower respiratory tract infection (URTI/LRTI) in the past four weeks prior to the pre-screening Visit 1, and during pre-screening and run-in periods. Start of run-in or treatment period should be postponed in case of infection. In case of URTI/LRTI during the run-in period, patients can be re-screened again 4 weeks after the resolution of the infection.
- •4.Patients with any exacerbation of their underlying asthma during the eight weeks prior to the pre-screening Visit 1. Visit 2 should be postponed in case of an exacerbation during the pre-screening period.
- •5.Patients with active allergic rhinitis requiring treatment with systemic corticosteroids.
- •6.Any of the following criteria are met during the pre-screening / run-in period (Visits 1 - 6):
- •- in clinic pre-bronchodilator FEV1 % predicted less than 40%,
- •- more than 12 puffs rescue salbutamol/albuterol HFA MDI per day for > 2 consecutive days,
- •- exacerbation of asthma.
- •7.Patients with a history of pneumonectomy or who are planning to undergo thoracotomy for any reason. Patients with a history of thoracotomy other than pneumonectomy should be evaluated as per exclusion criterion no.1.
- •8.Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the six weeks prior to the first screening visit 1.
- •9.Patients with two or more hospitalizations for asthma within the previous 12 months.
- •10.Patients with a recent history of myocardial infarction during the last twelve months or known coronary heart disease that requires treatment
- •11.Patients with a history of hospitalisation due to heart failure in the past twelve months
- •12.Patients with myocarditis or any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year
- •13.Patients with significant alcohol or drug abuse in the opinion of the investigator within the past two years
- •14.Patients with rheumatoid arthritis or other systemic diseases that require immune system modulating treatment
- •15.Patients with known hypersensitivity to ciclesonide or any other component of the trial medication
- •16.Patients suffering from or with a history of glaucoma, increased intraocular pressure, and/or cataracts
- •17.Pregnant or nursing women
- •18.Women of childbearing potential not using a highly effective method of birth control.
- •19.Patients who have been treated with anti-IgE-antibodies (e.g. omalizumab – Xolair®) or other immune system modulating antibodies such as TNF-blockers wit
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 mcg [2 actuations of 2.5 mcg] and 10 mcg [2 actuations of 5 mcg]) delivered by the Respimat Inhaler, and 48 weeks of twice daily Foradil (12 mcg) delivered by the Aerolizer Inhaler, in patients with Chronic Obstructive Pulmonary Disease (COPD) - NDChronic obstructive pulmonary disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-001933-84-ITBOEHRINGER ING.1,150
进行中（未招募）
1 期
A trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell functioMedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2014-001215-39-FIovo Nordisk A/S304
进行中（未招募）
1 期
Dose finding study on BI54903 (inhaled corticosteroid) administered twice daily via Respimat® inhaler in asthmatic patients inadequately controlled on SABA therapy.MedDRA version: 14.0Level: LLTClassification code 10003561Term: Asthma, unspecifiedSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2010-023167-17-SKBoehringer Ingelheim Pharma GmbH & Co. KG,755
进行中（未招募）
1 期
A trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell functioMedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2014-001215-39-ATovo Nordisk A/S304
进行中（未招募）
1 期
Study on BI 54903 (inhaled corticosteroid) administered twice daily via Respimat inhaler in patients with asthma inadequately controlled on low dose ICS.AsthmaEUCTR2010-023168-41-FRBoehringer Ingelheim Pharma GmbH & Co. KG,755